Ionis Pharmaceuticals (IONS) Stock Rating Upgraded by BidaskClub

Ionis Pharmaceuticals (NASDAQ:IONS) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a report released on Thursday.

IONS has been the subject of a number of other reports. TheStreet downgraded shares of Ionis Pharmaceuticals from a “c” rating to a “d+” rating in a research note on Tuesday, February 27th. ValuEngine downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd. Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 10th. BMO Capital Markets increased their price target on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 28th. Finally, Stifel Nicolaus increased their price target on shares of Ionis Pharmaceuticals from $55.00 to $57.00 and gave the stock a “hold” rating in a research note on Wednesday, February 28th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $52.15.

Shares of NASDAQ:IONS opened at $43.62 on Thursday. The stock has a market cap of $5,496.86, a PE ratio of 545.25 and a beta of 2.49. The company has a quick ratio of 5.15, a current ratio of 5.20 and a debt-to-equity ratio of 1.45. Ionis Pharmaceuticals has a 12 month low of $40.33 and a 12 month high of $65.51.



Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.10. Ionis Pharmaceuticals had a negative net margin of 1.18% and a negative return on equity of 1.94%. The firm had revenue of $172.00 million during the quarter, compared to the consensus estimate of $126.38 million. During the same period in the prior year, the firm posted $0.33 earnings per share. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. equities analysts anticipate that Ionis Pharmaceuticals will post -0.13 earnings per share for the current year.

In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 2,696 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $51.76, for a total value of $139,544.96. Following the sale, the senior vice president now owns 21,810 shares in the company, valued at $1,128,885.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Patrick R. O’neil sold 645 shares of the company’s stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $55.00, for a total transaction of $35,475.00. Following the completion of the sale, the senior vice president now owns 15,097 shares in the company, valued at approximately $830,335. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,472 shares of company stock worth $3,724,041. Corporate insiders own 2.13% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Envestnet Asset Management Inc. grew its holdings in Ionis Pharmaceuticals by 12.3% in the third quarter. Envestnet Asset Management Inc. now owns 51,094 shares of the company’s stock worth $2,590,000 after purchasing an additional 5,594 shares during the period. AXA purchased a new stake in Ionis Pharmaceuticals in the third quarter worth about $5,202,000. Bailard Inc. purchased a new stake in Ionis Pharmaceuticals in the fourth quarter worth about $292,000. California Public Employees Retirement System grew its holdings in Ionis Pharmaceuticals by 1.6% in the third quarter. California Public Employees Retirement System now owns 222,900 shares of the company’s stock worth $11,301,000 after purchasing an additional 3,600 shares during the period. Finally, Farallon Capital Management LLC grew its holdings in Ionis Pharmaceuticals by 43.3% in the fourth quarter. Farallon Capital Management LLC now owns 645,000 shares of the company’s stock worth $32,444,000 after purchasing an additional 195,000 shares during the period. Institutional investors and hedge funds own 90.72% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://dakotafinancialnews.com/2018/04/14/ionis-pharmaceuticals-ions-stock-rating-upgraded-by-bidaskclub.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply